Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 9:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiac Event Risk Clear all
Withdrawn Not applicable Interventional

Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges: Pilot Phase

NCT03791580
View directory record Official record
Conditions
Fall, Congestive Heart Failure, Chronic Kidney Failure, Adverse Drug Event
Interventions
Commitment nudge, Justification nudge
Behavioral
Lead sponsor
RAND
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 8, 2026, 9:32 PM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 8, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

NCT00249873
View directory record Official record
Conditions
Atrial Fibrillation, Vascular Risk
Interventions
clopidogrel (SR25990C), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
7,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2015 · Synced Sep 8, 2026, 9:32 PM EDT
Suspended Phase 3 Interventional

Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina

NCT00353067
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
veliflapon (DG-031)
Drug
Lead sponsor
deCODE genetics
Industry
Eligibility
35 Years and older
Enrollment
3,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
11
States / cities
Montgomery, Alabama • Jacksonville, Florida • Melrose Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2006 · Synced Sep 8, 2026, 9:32 PM EDT
Not listed Not applicable Interventional

A Prospective Evaluation of Health Services Outcomes and Emerging Cardiovascular Disease Biomarkers

NCT00820313
View directory record Official record
Conditions
Coronary Heart Disease, Biomarkers of Cardiovascular Disease
Interventions
Dr. Dean Ornish Program for Reversing Heart Disease
Behavioral
Lead sponsor
Preventive Medicine Research Institute
Other
Eligibility
21 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Sausalito, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2009 · Synced Sep 8, 2026, 9:32 PM EDT
Terminated Phase 4 Interventional Results available

Risk Factor Control Before Orthopedic Surgery

NCT01837069
View directory record Official record
Conditions
Osteoarthritis, Cardiovascular Disease
Interventions
Metoprolol, Lisinopril, Atorvastatin, Lifestyle counseling
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 8, 2026, 9:32 PM EDT
Withdrawn No phase listed Observational

The Ability Of The PD2i Cardiac Analyzer To Predict Risk Of Ventricular Tachyarrhythmic Events

NCT00510731
View directory record Official record
Conditions
Tachycardia, Ventricular, Cardiac Sudden Death
Interventions
Not listed
Lead sponsor
Vicor Technologies, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
19
States / cities
Los Angeles, California • San Ramon, California • Walnut Creek, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 8, 2026, 9:32 PM EDT
Completed Phase 3 Interventional

Raloxifene Use for The Heart

NCT00190593
View directory record Official record
Conditions
Cardiovascular Diseases, Breast Neoplasms
Interventions
raloxifene, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older · Female only
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2007 · Synced Sep 8, 2026, 9:32 PM EDT
Withdrawn No phase listed Observational

T2 Heart Mapping in AMI Population for the Prediction of Short Term Major Adverse Cardiovascular Events

NCT01796743
View directory record Official record
Conditions
Myocardial Infarction, Acute
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 8, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 8, 2026, 9:32 PM EDT
Withdrawn No phase listed Observational

Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients

NCT01809730
View directory record Official record
Conditions
Coronary Artery Disease, Cerebral Vascular Disease, Peripheral Artery Disease, Renal Insufficiency, Diabetes, COPD, Hypertension, Active Smoker, Cancer, CHF, Prior DVT/PE
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 8, 2026, 9:32 PM EDT
Terminated No phase listed Observational

Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke

NCT05421533
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Fullerton, California • Boca Raton, Florida • Homestead, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 8, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

NCT00621855
View directory record Official record
Conditions
Coronary Disease
Interventions
placebo, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Sep 8, 2026, 9:32 PM EDT
Recruiting Phase 3 Interventional

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

NCT07613294
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
Interventions
Lepodisiran, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
La Jolla, California • Northridge, California • Torrance, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 8, 2026, 9:32 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

NCT06307652
View directory record Official record
Conditions
Heart Failure and Impaired Kidney Function
Interventions
balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
4,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
166
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 8, 2026, 9:32 PM EDT
Recruiting Not applicable Interventional

Digital Monitoring for Patients Post Coronary Interventions to Reduce Risk for Recurrent Adverse Cardiovascular Events

NCT06114615
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
LiveCare, Text Messages, Conventional Care
Device · Behavioral · Other
Lead sponsor
University of California, Davis
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 8, 2026, 9:32 PM EDT
Terminated Phase 3 Interventional Results available

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

NCT01975376
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
bococizumab (PF-04950615), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
545
States / cities
Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 339 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 8, 2026, 9:32 PM EDT
Withdrawn Not applicable Interventional

Heart Rate Variability (HRV) to Evaluate Surgical Risk on Patients on Beta Blockers

NCT01330654
View directory record Official record
Conditions
Cardiac Event Risk
Interventions
metoprolol
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Sep 8, 2026, 9:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Eliminate Risk of Cardiac Surgical Site Events

NCT01425697
View directory record Official record
Conditions
Surgical Site Infections
Interventions
2% Chlorhexidine Gluconate cloths, Standard of Care preoperative preparation.
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
4
States / cities
Lexington, Kentucky • Ridgewood, New Jersey • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 8, 2026, 9:32 PM EDT
Recruiting Phase 2 Interventional

The CARDIOPROTECT Trial

NCT07654426
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions
Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 8, 2026, 9:32 PM EDT
Recruiting No phase listed Observational

Tezspire Cardiac Events PASS

NCT06951867
View directory record Official record
Conditions
Cardiovascular Events, MACE
Interventions
Tezepelumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
16,640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 8, 2026, 9:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Color Priming and Patient Decision-Making in the Emergency Department: Priming "Threat" in Patients With Low-Risk Chest Pain

NCT04749147
View directory record Official record
Conditions
Chest Pain, Cardiac Event
Interventions
Black and White Printed Survey, Red Printed Survey
Other
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 8, 2026, 9:32 PM EDT
Recruiting Phase 3 Interventional

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060
View directory record Official record
Conditions
Heart Failure
Interventions
Baxdrostat and dapagliflozin, Placebo and dapagliflozin
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
11,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
198
States / cities
Birmingham, Alabama • Centreville, Alabama • Fairhope, Alabama + 176 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 8, 2026, 9:32 PM EDT
Completed No phase listed Observational

Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy

NCT00753233
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Up to 21 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 8, 2026, 9:32 PM EDT